VAH drug combo before stem cell transplant for hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (VAH) as a 'bridge' to prepare patients with acute myeloid leukemia (AML) that has come back or not responded to standard treatment for a stem cell transplant. The goal is to see if VAH can help achieve remission and improve transplant outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 70 years old.
- You must have acute myeloid leukemia (AML) that has returned after treatment or has not responded to standard chemotherapy.
- Your leukemia must be confirmed by specific bone marrow tests, including genetic and molecular tests.
- Your overall health must be fairly good (ECOG score of 2 or less), and your heart, liver, and kidney function must be within acceptable limits.
- If you have a specific genetic type (RUNX1::RUNX1T1), you must have evidence of residual disease after consolidation therapy.
- You cannot have serious heart problems, active infections, or autoimmune diseases like lupus or rheumatoid arthritis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This study tests a new combination of chemotherapy drugs (called VABu) used before a stem cell transplant to prepare your body. The goal is to see if it is safe and effective for people with AML in first remission.
This trial studies a combination of two medicines (venetoclax and azacitidine) as a bridge to a stem cell transplant for people with a hard-to-treat type of AML (like secondary AML or with low bone marrow cells). The goal is to get the leukemia under control so a transplant can be done successfully.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
Hear when a new Relapse Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.